Consequently, genes involved in DNA damage processing are targets for tumor therapy.7–10 Ataxia telangiectasia mutated (ATM) together with ataxia telangiectasia and Rad3-related protein (ATR) and DNA-dependent protein kinase catalytic subunit (DNA-PKCS) constitutes the core of the DDR.11 DNA damage agents have shown favorable efficacy in anticancer therapy, which has accelerated the development of cancer chemotherapy. This evidence concerns the gene ATR and neoplasm.